New Potential Therapy for Glioblastoma Targets Tumor Ecosystem

A research team believes they have identified a potential new approach to combating glioblastoma, one of the deadliest brain cancers. They developed an experimental therapy designed to exploit a perceived critical weakness in the disease. Although this treatment is still several years away from being available to patients, having only been tested in preclinical models, it is generating interest due to its novel approach.

The urgency for new treatments is high. Glioblastoma remains a highly lethal cancer, with the average survival time after diagnosis being only 12 to 18 months. Long-term survival is rare, with just about 5% of patients living beyond five years. Researchers suggest that a fundamental issue lies in how glioblastoma has traditionally been perceived. Instead of being an isolated mass of malignant cells, the tumor is part of an extensive network of surrounding cells that provide vital support for its survival and growth.

“Solid tumors like glioblastoma are not just a mass of cancerous cells; they are an ecosystem of cancerous and non-cancerous cells that grow and support each other,” said Shan Grewal, a PhD candidate in biochemistry and biomedical sciences at McMaster University and co-lead author of the study.

Grewal and his team propose that focusing solely on cancer cells fails to account for other significant biological processes crucial for the disease’s persistence.

The researchers concentrated on a protein called GPNMB, which was found both on glioblastoma cells and macrophages—immune cells that associate closely with the tumor. This observation led them to a new therapeutic angle. They engineered CAR-T cells to recognize GPNMB wherever it appeared. This strategy aimed to disrupt multiple components of the disease concurrently.

“We identified GPNMB as a protein found on both glioblastoma cells and tumor-supporting macrophages,” Grewal stated. “This allowed us to use a CAR-T cell strategy that can attack glioblastoma on two fronts at once.”

This approach supports a growing consensus that effective glioblastoma therapies must address more than just cancer cells.

“Instead of treating the tumor as only a mass of cancer cells, we suggest that we must treat glioblastoma as a connected tumor-immune ecosystem,” said Sheila Singh, a professor of surgery at McMaster University.

During preclinical testing, this therapy successfully eliminated detectable tumors and achieved long-term, disease-free survival in glioblastoma models, including those generated from human patient tumors.

The shift in understanding comes as the scientific community explores how immunotherapy can be more effective against brain cancer. While immune-cell therapies have been successful for some blood cancers, applying them to glioblastoma has been more challenging. Researchers suspect the tumor’s ability to alter its surrounding environment plays a crucial role.

“Many of us hoped immunotherapy could change outcomes for GBM patients, but unfortunately, long-term success has been difficult to achieve,” Grewal noted. “The field now largely recognizes one of the major barriers is the highly suppressive ecosystem glioblastoma builds around itself.”

Despite these promising findings, significant challenges remain. The therapy has not yet undergone clinical trials. Researchers need to determine patient suitability, the optimal delivery method, and complete necessary safety and regulatory requirements.

Grewal emphasizes that the discovery should be seen as a preliminary advancement, not an immediate treatment.

“Glioblastoma remains one of the most devastating cancers, and patients deserve new options,” he said. “For patients and families, the key message is that this is not yet an available treatment, but it’s a promising step in the right direction.”